(0.66%) 5 079.75 points
(0.46%) 38 243 points
(0.83%) 17 583 points
(0.92%) $79.73
(2.38%) $1.978
(-0.03%) $2 310.20
(-0.89%) $26.51
(0.80%) $962.50
(0.23%) $0.935
(0.36%) $11.07
(0.12%) $0.799
(-1.81%) $91.57
1.09% £ 987.20
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
Объем за сегодня | 720 330 |
Средний объем | 3.69M |
Рыночная капитализация | 8.63B |
EPS | £0 ( 2024-05-01 ) |
Дата следующего отчета о доходах | ( £0 ) 2024-08-01 |
Last Dividend | £18.38 ( 2023-03-30 ) |
Next Dividend | £0 ( N/A ) |
P/E | 41.13 |
ATR14 | £0.613 (0.06%) |
Объем Корреляция
Smith & Nephew plc Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Smith & Nephew plc Корреляция - Валюта/Сырье
Smith & Nephew plc Финансовые показатели
Annual | 2023 |
Выручка: | £5.55B |
Валовая прибыль: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2023 |
Выручка: | £5.55B |
Валовая прибыль: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2022 |
Выручка: | £5.22B |
Валовая прибыль: | £3.68B (70.47 %) |
EPS: | £0.250 |
FY | 2021 |
Выручка: | £5.21B |
Валовая прибыль: | £3.67B (70.40 %) |
EPS: | £0.598 |
Financial Reports:
No articles found.
Smith & Nephew plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£12.91 (N/A) |
£0 (N/A) |
£18.38 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £3.45 | 1993-05-10 |
Last Dividend | £18.38 | 2023-03-30 |
Next Dividend | £0 | N/A |
Payout Date | 2023-05-17 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | £440.59 | -- |
Avg. Dividend % Per Year | 1.26% | -- |
Score | 4.39 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 6.49 | |
Div. Directional Score | 7.49 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £26.91 | 1.93% |
2019 | £28.49 | 1.99% |
2020 | £29.73 | 1.62% |
2021 | £27.12 | 1.73% |
2022 | £31.31 | 2.40% |
2023 | £18.38 | 1.64% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PCFT.L | Dividend Knight | 2023-08-03 | Semi-Annually | 11 | 1.80% | |
FEVR.L | Dividend Knight | 2023-09-28 | Semi-Annually | 10 | 0.75% | |
AA4.L | Dividend King | 2023-07-13 | Semi-Annually | 9 | 7.97% | |
TAM.L | Dividend Knight | 2023-07-06 | Semi-Annually | 8 | 1.85% | |
KNM.L | Dividend Knight | 2023-09-28 | Annually | 14 | 0.97% | |
CFYN.L | Dividend Knight | 2023-07-13 | Annually | 33 | 1.92% | |
RCN.L | Ex Dividend Junior | 2023-12-07 | Annually | 11 | 1.07% | |
GNS.L | Dividend Knight | 2023-11-09 | Semi-Annually | 24 | 0.38% | |
APAX.L | Dividend Knight | 2023-09-14 | Semi-Annually | 9 | 3.81% | |
TRIG.L | Dividend Knight | 2023-08-10 | Quarterly | 11 | 3.09% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0474 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0503 | 1.500 | -0.552 | -0.828 | [0.1 - 1] |
payoutRatioTTM | 1.243 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.569 | 0.800 | -1.359 | -1.087 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.85 | -7.28 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.591 | -1.500 | 7.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.701 | 1.000 | 1.644 | 1.644 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.123 | 1.000 | 9.54 | 9.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.197 | 1.000 | -0.0159 | -0.0159 | [0.2 - 2] |
assetTurnoverTTM | 0.556 | 0.800 | 9.63 | 7.70 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.73 | 1.000 | 5.99 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0503 | 2.50 | -0.355 | -0.828 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.93 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.86 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.243 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 139.73 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.110 | 1.000 | 9.76 | 0 | [0.1 - 0.5] |
Total Score | 6.49 |
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа